Skip to main content

New Pure Style ETFs by Guggenheim Investments

Out looking for new products today. Guggenheim Investments has a new class of ETFs called Pure Style ETFs.


The funds are based on the concept that the, "potential drawback of actively managed mutual funds and traditional cap‐weighted style indices is a lack of style purity. This may undermine portfolio optimization and Guggenheim Pure Style ETFs seek to address this shortcoming with a unique approach, offering only “pure” exposure to value and growth investing."
 
Guggenheim lists about 7 funds in this new class of funds. If you would like more information on how this class of funds can help you grow you wealth, call us at 1-866-801-3359 or visit our website at UCS Financial Advisors and fill out and submit the secured form on our Wealth Products page requesting more information in the comments section of the form.

**Please note we are in no way affiliated with Guggenheim Investments or any of its funds or investments, nor are we paid to recommend any of their funds or investments. Our research and recommendations are based purely on our own in-house research methods and abilities.
 
Brought to you by: ThrushyMedia

Comments

Popular posts from this blog

Morning Update

By Rick Walter Still working on putting together a strong biotech portfolio. Here is a good general article on the state of the biotech industry that was posted yesterday on the online Wall Street Journal's site- Biotech Stocks Hot Right Now, Ho-Hum in the Long Run.

Portfolio Update

By Rick Walter I have posted a new Biotechnology portfolio . It's total return as of November 25, 2009 is 3.4%. However, to download and use it you will have to subscribe to the portfolio, of course. On an important note, I consider each portfolio to be well diversified in its particular sector but I've recently decided to add stock futures and options positions to each portfolio which will increase each portfolio's return but lower the risks going forward.

Biotech Pump and Dump

By Rick Walter Building a good Biotechnology portfolio has turned out to be a bit of a task. I have one on the table, but feel that it's a little too aggressive and risky, especially for today's market. Funding for most Biotech ventures- old or new, have either dried up or have been put on hold. This portfolio that I am building is too much of a pure Biotech play. It would be feast or famine on the returns. Let me explain. I remember when I was a young broker, I worked for this small outfit in Florida where the office manager and a few other brokers, including myself, would get all pumped up over a stock called Celi. I believe that the stock is now trading on the Amex as (Cel-Sci: CVM ). Well the stock was always on the verge of getting approval for some phase of cancer treatment therapy. Whenever the company released news, we would run the stock up as high as the market makers would let us run it- ($1.30 to $2.30 per share) before we banged it back down to previous lows of .30...